Holen Sie sich die Stockscreener-App
0.695
3.94%
-0.0285
Schlusskurs vom Vortag:
$0.7235
Offen:
$0.716
24-Stunden-Volumen:
862.22K
Relative Volume:
3.46
Marktkapitalisierung:
$8.75M
Einnahmen:
$123.30K
Nettoeinkommen (Verlust:
$-11.95M
KGV:
-0.4507
EPS:
-1.5421
Netto-Cashflow:
$-12.57M
1W Leistung:
-8.65%
1M Leistung:
-15.24%
6M Leistung:
-2.85%
1J Leistung:
-53.04%
1-Tages-Spanne:
$0.685
$0.7362
1-Wochen-Bereich:
$0.675
$0.82
52-Wochen-Spanne:
$0.548
$1.69
Aprea Therapeutics Inc Stock (APRE) Company Profile
Firmenname
Aprea Therapeutics Inc
Sektor
Branche
Telefon
215-948-4119
Adresse
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.695 | 9.58M | 123.30K | -11.95M | -12.57M | -1.5421 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-28 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-06-22 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-10-28 | Eingeleitet | JP Morgan | Neutral |
| 2019-10-28 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Aprea Therapeutics Inc Aktie (APRE) Neueste Nachrichten
Aprea Therapeutics, Inc. (APRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aprea Therapeutics to present WEE1 inhibitor trial data in November - Investing.com
Aprea Therapeutics to present WEE1 inhibitor trial data in November By Investing.com - Investing.com India
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium - The Manila Times
Aprea Therapeutics to Present Updated Interim Phase 1 Data - GlobeNewswire
Aprea Therapeutics | DEFA14A: Others - Moomoo
Aprea Therapeutics at H.C. Wainwright conference: early data lifts outlook By Investing.com - Investing.com India
Aprea Puts Cancer Drug Pipeline Before Investors - MyChesCo
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - stocktwits.com
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Doylestown's Aprea Therapeutics Expands Patent Portfolio Protecting Its Two Lead Cancer Drugs - BioBuzz
Dose Escalation, Combination Strategy Keep Aprea Ahead In Its Oncology Trials - Clinical Leader
Aprea Therapeutics Inc (APRE:UR): Stock Price, Quote and News - BNN Bloomberg
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - marketscreener.com
Aprea Therapeutics Expands Patent Portfolio for Precision Oncology Programs - Minichart
Aprea Therapeutics reports patent portfolio of 58 patents - Investing.com
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com Canada
Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ) - Seeking Alpha
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateEarnings Expansion Phase - vinanet.vn
Aprea (APRE) Stock: Advances 1.19% to $0.64 in the Latest Reading; Market Levels: the Current Price Sits Inside the Supplied Technical Range in the Current UpdateHigh Volume Node - vinanet.vn
Aprea Expands Cancer Trial as APR-1051 Shows Early Activity - MyChesCo
Aprea (APRE) Q1 2026 Scorecard: EPS Exceeds Its Estimate in the Latest Session; Stock Move: The Market Price Declines 2.61% at the CloseInterim Report - careplusvn.com
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotChandelier Stop - vinanet.vn
APRE Q1 2026 Earnings: Narrower-than-Expected Loss Signals Disciplined ExecutionEarnings Recovery Stocks - Vinanet
Aprea Therapeutics (APRE) Edges Higher by 1.34% as Shares Hover Above Key SupportStrangle Setup - vinanet.vn
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics (APRE) Consolidates Near Support as Shares Dip 1.76%Mid Cap Momentum - vinanet.vn
Oppenheimer Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aprea Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
APRE: APR-1051 demonstrates promising early efficacy and safety, driving a biomarker-focused oncology pipeline - TradingView
Aprea Therapeutics advances APR-1051 oncology pipeline progress - TipRanks
Form 8K Aprea Therapeutics Inc For: 12 August - Investing.com India
Aprea Therapeutics 2Q 2026: Revenue $0 Net loss $(3.59M), EPS $(0.07) — 10-Q Summary - TradingView
Aprea Therapeutics (NASDAQ: APRE) extends cash runway with $41M balance and trial updates - Stock Titan
Aprea Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Aprea Therapeutics Reports $3.6 Million Q2 Net Loss - Quiver Quantitative
Aprea Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Price to earnings forward of Aprea Therapeutics, Inc. – NASDAQ:APRE - TradingView
Aprea Therapeutics Inc (APRE) Stock News Today - TradingKey
Aprea Therapeutics Inc expected to post a loss of 23 cents a shareEarnings Preview - TradingView
Aprea Therapeutics, Inc. (APRE) stock price, news, quote and history - Yahoo Finance Singapore
Aprea Expands APR-1051 Trial as Enrollment Accelerates - mychesco.com
APRE Q2'26 Earnings: EPS estimate is (0.18) USD - TradingView
Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors - TipRanks
Lipocine Appoints Michael J. Grissinger to Board of Directors - Yahoo Finance
APRE Q1 2026 Earnings: Narrower-than-Expected Loss Beats Estimates, Shares Slide 2.36%High Growth Earnings - dars.gov.et
Aprea Therapeutics plans Q4 2026 data update for APR-1051 trial - Investing.com Nigeria
Finanzdaten der Aprea Therapeutics Inc-Aktie (APRE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aprea Therapeutics Inc-Aktie (APRE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Jan 30 '26 |
Buy |
0.89 |
5,700 |
5,073 |
33,433 |
| Duey Marc | Director |
Dec 10 '25 |
Buy |
1.17 |
21,459 |
25,000 |
256,155 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Dec 10 '25 |
Buy |
1.17 |
5,000 |
5,825 |
27,733 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):